JEN-HUNG YANG2026-10-162026-10-162004-01-01Pure ID: 15357722Pure UUID: 796747e4-01c7-4b3e-8669-ff35903d486ahttps://www.scopus.com/pages/publications/34447291564https://scholars.csmu.edu.tw/handle/123456789/30657Tamoxifen was used to determine the effects of N-acetyltransferase(NAT) activity and 2-aminofluorene(2-AF)-DNA adduct formation in human breast cancer cells. Breast cancer cells were categorized into two groups based on the status of estrogen receptor, ER (+) and ER (-). 2-AF-DNA adduct formations in breast cancer cells are 2.58± 0.39 pmol adduct/mg DNA for ER (+) and 2.74± 0.46 pmol adduct/mg DNA for ER (-), respectively. Co-treatment with 1 μM tamoxifen inhibited DNA-adduct formations up to 65% in ER (+) and 61% in ER (-), respectively. The inhibition of Tamoxifen on DNA adduct formation between ER (+) and ER (-) cell was not significantly different. The results of the N-acetyltransferase activity in human breast cancer cells were inhibited by tamoxifen in a dose dependent manner. Tamoxifen inhibited 50.0% and 42.8% of Km in ER (+) and ER (-), 58.2% and 35.6% of Vmax, respectively. Based on the kinetic study of N-acetyltransferase activity, tamoxifen plays a non-competitive role in the acetylation reaction. This study demonstrates that tamoxifen inhibited not only NAT activity but also DNA-adduct formation in human breast cancer cells, regardless of the status of estrogen receptor. These findings could provide a clue that tamoxifen has chemoprevention effects in breast cancer.17enEffects of tamoxifen on DNA adduct formation and arylamines N-acetyltransferase activity in human breast cancer cellsjournal article